Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

1 Sept 2024

Abstract excerpt

Abstract: Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality. Multiple clinical trials with PARPi monotherapy...

Source

Identifiers

PMID: 39308935
DOI: 10.2147/cmar.s411023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsPMID 39308935Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

Advances in PARP Inhibitors for Prostate CancerSemantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancerSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer.Semantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.